Profile
Sector:
HealthcareCountry:
United StatesIPO:
25 June 2015Website:
http://www.lantheus.comNext earnings report:
06 November 2024Last dividends:
N/ANext dividends:
N/APrice
pre-market | 8 min agoDividend
Analysts recommendations
Institutional Ownership
LNTH Latest News
BEDFORD, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, applauds the Centers for Medicare & Medicaid Services' (CMS) final rule for the calendar year 2025 Medicare Hospital Outpatient Prospective Payment System (OPPS). The rule, announced and detailed on the CMS website late Friday, recognizes the value of and ensures broad patient access to specialized diagnostic radiopharmaceuticals by improving the accuracy of payment amounts for these products.
BEDFORD, Mass., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, November 6, 2024, to discuss its financial and operating results for the third quarter of 2024.
Study met its primary endpoint, demonstrating significant improvement in radiographic progression-free survival Overall Response Rate was 38.1% vs. 12.0% for the ARPI switch arm, including 9.3% Complete Responses Patients demonstrated statistically significant improvement in time to reduction of health-related quality of life (HRQoL) as measured by Functional Assessment of Cancer Therapy—Prostate (FACT-P) Interim Overall Survival Crossover Adjusted Hazard Ratio was
BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Julie Eastland, an experienced biotechnology and financial executive, to Lantheus' Board of Directors (“Board”), effective as of September 3, 2024. As an independent director, Ms. Eastland will serve as a member of the Board's Audit Committee. Following the appointment of Ms. Eastland, the Board will be comprised of ten directors, eight of whom are independent.
BEDFORD, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced Brian Markison, Chief Executive Officer, will present at the Morgan Stanley 22nd Annual Global Healthcare Conference at 7:45 a.m. ET on Wednesday, September 4.
Second Quarter 2024 Worldwide revenue of $394.1 million, an increase of 22.5% from second quarter 2023 Completed three strategic transactions to expand innovative pipeline GAAP fully diluted earnings per share of $0.88, compared to $1.33 in second quarter 2023. Adjusted fully diluted earnings per share of $1.80 compared to $1.54 in the second quarter 2023, reflective of inter-quarter investment in business development and R&D.
Medicare will likely soon change how it pays for diagnostic radiopharmaceuticals. Lantheus should be a big winner from this reimbursement change.
BEDFORD, Mass., July 10, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced that it welcomes the Centers for Medicare & Medicaid Services' (CMS') Proposed Medicare Hospital Outpatient Prospective Payment System (OPPS) Rule for calendar year 2025 for improved payment for specialized diagnostic radiopharmaceuticals to support patient access for Medicare beneficiaries.
BEDFORD, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Jamie Spaeth to its Executive Team as Chief People Officer.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
What type of business is Lantheus Holdings?
Lantheus Holdings, Inc. is one of the world leaders in the development, manufacturing, and commercialization of innovative agents and products for medical imaging, which help doctors in the diagnosis and treatment of cardiovascular and other diseases. Clinicians use the company's agents and products in a variety of imaging methods, including echocardiography and nuclear imaging. The company was founded in 1956, with its headquarters located in Billerica, Massachusetts, USA. The company's current portfolio consists of ten commercial products. The current products include contrast agents for ultrasound and medical radiopharmaceuticals for nuclear imaging.
What sector is Lantheus Holdings in?
Lantheus Holdings is in the Healthcare sector
What industry is Lantheus Holdings in?
Lantheus Holdings is in the Drug Manufacturers - Specialty & Generic industry
What country is Lantheus Holdings from?
Lantheus Holdings is headquartered in United States
When did Lantheus Holdings go public?
Lantheus Holdings initial public offering (IPO) was on 25 June 2015
What is Lantheus Holdings website?
https://www.lantheus.com
Is Lantheus Holdings in the S&P 500?
No, Lantheus Holdings is not included in the S&P 500 index
Is Lantheus Holdings in the NASDAQ 100?
No, Lantheus Holdings is not included in the NASDAQ 100 index
Is Lantheus Holdings in the Dow Jones?
No, Lantheus Holdings is not included in the Dow Jones index
When was Lantheus Holdings the previous earnings report?
No data
When does Lantheus Holdings earnings report?
The next expected earnings date for Lantheus Holdings is 06 November 2024